AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18689560 — intervention group
Group type: EXPERIMENTAL
Intervention: DietMatePro
Number of subjects: 174
Study 18689560 — intervention group
Group type: COMPARATOR
Intervention: Paper food diary
Number of subjects: 174
Study 15975098 — intervention group
Group type: EXPERIMENTAL
Intervention: IDetmorn+din
Number of subjects: 400
Study 15975098 — intervention group
Group type: EXPERIMENTAL
Intervention: IDetmorn+bed
Number of subjects: 400
Study 15975098 — intervention group
Group type: COMPARATOR
Intervention: NPHmorn+bed
Number of subjects: 400
Study 15975098 — intervention group
Group type: EXPERIMENTAL
Intervention: IDetmorn+din and IDetmorn+bed
Number of subjects: 400
Study 12916149 — intervention group
Group type: EXPERIMENTAL
Intervention: Precolposcopy educational sessions
Number of subjects: 47
Study 10480523 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients
Number of subjects: 70
Study 10480523 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes patients with CHD
Number of subjects: 70
Study 10480523 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic control subjects
Number of subjects: 70
Study 9196992 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin tolerance test (0.1 U/kg of crystalline insulin)
Number of subjects: 11
Study 9196992 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous glucose tolerance test (0.3 g glucose/kg followed by 0.02 U/kg of crystalline insulin)
Number of subjects: 11
Study 1933160 — intervention group
Group type: EXPERIMENTAL
Intervention: Bard Biocath catheter (16 F 10‐ml balloon)
Number of subjects: 69
Study 1933160 — intervention group
Group type: COMPARATOR
Intervention: Silastic catheter (16 F 10‐ml balloon)
Number of subjects: 69
Study 1933160 — intervention group
Group type: EXPERIMENTAL
Intervention: Bard Biocath catheter (non-encrusted)
Number of subjects: 69
Study 1933160 — intervention group
Group type: COMPARATOR
Intervention: Silastic catheter (non-encrusted)
Number of subjects: 69
Study 7017490 — intervention group
Group type: EXPERIMENTAL
Intervention: guacetisal
Number of subjects: 28
Study 7017490 — intervention group
Group type: COMPARATOR
Intervention: dimethylaminophenazone guaiacolglycolate and calcium ethylcamphorate
Number of subjects: 28
Study 30741854 — intervention group
Group type: EXPERIMENTAL
Intervention: Crowdsourced video intervention
Number of subjects: 1173
Study 30741854 — intervention group
Group type: COMPARATOR
Intervention: Social marketing video intervention
Number of subjects: 1173
Study 27933401 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal rifaximin (RFX) for 6 days
Number of subjects: 300
Study 27933401 — intervention group
Group type: EXPERIMENTAL
Intervention: Dequalinium chloride (DQC) for 6 days
Number of subjects: 300
Study 27933401 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 24934738 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-session self-hypnosis training intervention without audio recordings for home practice
Number of subjects: 100
Study 24934738 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight-session self-hypnosis training intervention with recordings
Number of subjects: 100
Study 24934738 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-session self-hypnosis training intervention with recordings and brief weekly reminder telephone calls
Number of subjects: 100
Study 24934738 — intervention group
Group type: COMPARATOR
Intervention: Active (biofeedback) control intervention
Number of subjects: 100
Study 24934738 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis (combined groups)
Number of subjects: 100
Study 23900128 — intervention group
Group type: EXPERIMENTAL
Intervention: 800ml oral carbohydrate fluid 8 h before the operation and 400ml oral carbohydrate fluid 2 h before the operation
Number of subjects: 40
Study 23900128 — intervention group
Group type: COMPARATOR
Intervention: Stopped oral implementation 8 h before the operation
Number of subjects: 40
Study 21062637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 600 mg
Number of subjects: 10
Study 21062637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 21062637 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.26 mg/kg bolus followed by 0.25 mg/kg IV infusion)
Number of subjects: 10
Study 20027430 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc phosphate cement
Number of subjects: 60
Study 20027430 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F resin-based cement
Number of subjects: 60
Study 20027430 — intervention group
Group type: COMPARATOR
Intervention: Post cementation periods (immediate, 72 h, 4 months)
Number of subjects: 60
Study 17267590 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection of Escherichia coli endotoxin (0.3 ng/kg)
Number of subjects: 10
Study 17267590 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of Escherichia coli endotoxin (0.3 ng/kg over 4 hours)
Number of subjects: 10
Study 17267590 — intervention group
Group type: COMPARATOR
Intervention: Saline administration
Number of subjects: 10
Study 15598992 — intervention group
Group type: EXPERIMENTAL
Intervention: Body tilt (pitch axis) with varying amplitudes
Number of subjects: 14
Study 12528557 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia miltiorrhiza and shengmai (SS)
Number of subjects: 15
Study 12528557 — intervention group
Group type: COMPARATOR
Intervention: Obstructive jaundice (OJ) group (no SS)
Number of subjects: 15
Study 12528557 — intervention group
Group type: COMPARATOR
Intervention: Non-OJ group
Number of subjects: 15
Study 9694306 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 min nap
Number of subjects: 30
Study 9694306 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 min nap
Number of subjects: 30
Study 9694306 — intervention group
Group type: COMPARATOR
Intervention: No nap
Number of subjects: 30
Study 8128083 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary coronary angioplasty
Number of subjects: 33
Study 2622724 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyerobics visual skills training for 4 weeks
Number of subjects: 20
Study 2622724 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 20
Study 769550 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin at a daily dose of 1.2 mg/kg body weight, administered by intramuscular injection at 8 or 12 hour intervals
Number of subjects: 32
Study 769550 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin
Number of subjects: 32
Study 31605377 — intervention group
Group type: COMPARATOR
Intervention: Hand file
Number of subjects: 120
Study 31605377 — intervention group
Group type: COMPARATOR
Intervention: ProTaper Universal retreatment file
Number of subjects: 120
Study 31605377 — intervention group
Group type: COMPARATOR
Intervention: D‐RaCe retreatment file
Number of subjects: 120
Study 31605377 — intervention group
Group type: COMPARATOR
Intervention: Reciproc file
Number of subjects: 120
Study 31605377 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciproc system
Number of subjects: 120
Study 31605377 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal retreatment
Number of subjects: 120
Study 31605377 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐RaCe retreatment
Number of subjects: 120
Study 31493177 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib induction at 150 mg/day for 3 months followed by cytotoxic chemotherapy (platinum plus pemetrexed, with or without bevacizumab)
Number of subjects: 20
Study 31493177 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib induction
Number of subjects: 20
Study 31493177 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy after erlotinib induction
Number of subjects: 20
Study 31493177 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 20
Study 28928574 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline approach LESI
Number of subjects: 60
Study 28928574 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal approach LESI
Number of subjects: 60
Study 28928574 — intervention group
Group type: EXPERIMENTAL
Intervention: Paramedian approach LESI
Number of subjects: 60
Study 25946126 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 and PTA 5289 lozenges (108 CFU of each strain/lozenge)
Number of subjects: 44
Study 25946126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 23075031 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise at 65% [Vdot]O(2)max
Number of subjects: 12
Study 23075031 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise at 75% [Vdot]O(2)max
Number of subjects: 12
Study 23075031 — intervention group
Group type: COMPARATOR
Intervention: No-exercise condition
Number of subjects: 12
Study 23075031 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise at varying intensities
Number of subjects: 12
Study 21240026 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment program of obesity
Number of subjects: 91
Study 21240026 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment program of obesity
Number of subjects: 91
Study 21240026 — intervention group
Group type: EXPERIMENTAL
Intervention: Total CTT measurement
Number of subjects: 91
Study 21240026 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet evaluation
Number of subjects: 91
Study 18496340 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐TCP combined with local bone obtained from decompression (group A, n = 32)
Number of subjects: 62
Study 18496340 — intervention group
Group type: COMPARATOR
Intervention: autogenous iliac crest bone graft plus decompression bone (group B, n = 30)
Number of subjects: 62
Study 17000194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sainte‐Anne's Hospital reshaped minced‐ or pureed‐texture foods with thickened beverages
Number of subjects: 17
Study 17000194 — intervention group
Group type: COMPARATOR
Intervention: Traditional nourishment
Number of subjects: 17
Study 14530859 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20 ppm
Number of subjects: 15
Study 14530859 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sildenafil (0.35 mg/kg over 20 min)
Number of subjects: 15
Study 14530859 — intervention group
Group type: COMPARATOR
Intervention: Both groups (iNO and sildenafil)
Number of subjects: 15
Study 10965414 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin (0.5 mg) with DHEC (20 mg)
Number of subjects: 12
Study 10965414 — intervention group
Group type: COMPARATOR
Intervention: Digoxin (0.5 mg) without DHEC
Number of subjects: 12
Study 10965414 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin with DHEC
Number of subjects: 12
Study 10965414 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 12
Study 8774208 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid chemoprophylaxis (10 to 15 mg/kg, twice-weekly)
Number of subjects: 2960
Study 1615986 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytobrush‐spatula
Number of subjects: 2015
Study 1615986 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayne Pap Brush
Number of subjects: 2015
Study 1615986 — intervention group
Group type: COMPARATOR
Intervention: cotton swab‐spatula
Number of subjects: 2015
Study 6746947 — intervention group
Group type: EXPERIMENTAL
Intervention: Contract/recording
Number of subjects: 25
Study 6746947 — intervention group
Group type: EXPERIMENTAL
Intervention: Contract/recording plus instructions for positive reinforcement
Number of subjects: 25
Study 6746947 — intervention group
Group type: COMPARATOR
Intervention: No contract/no recording
Number of subjects: 25
Study 31922462 — intervention group
Group type: COMPARATOR
Intervention: Collagenase clostridium histolyticum
Number of subjects: 280
Study 31277694 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention focused on promoting infant sleeping and self-soothing
Number of subjects: 300
Study 31277694 — intervention group
Group type: COMPARATOR
Intervention: Child safety control intervention
Number of subjects: 300
Study 31277694 — intervention group
Group type: EXPERIMENTAL
Intervention: Responsive parenting intervention
Number of subjects: 300
Study 29029210 — intervention group
Group type: EXPERIMENTAL
Intervention: lesinurad 400 mg daily
Number of subjects: 214
Study 29029210 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 214
Study 25683593 — intervention group
Group type: EXPERIMENTAL
Intervention: Outflow tract PVCs
Number of subjects: 146
Study 25683593 — intervention group
Group type: COMPARATOR
Intervention: Non-outflow tract PVCs
Number of subjects: 146
Study 25683593 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic reverse remodeling
Number of subjects: 146
Study 25683593 — intervention group
Group type: EXPERIMENTAL
Intervention: PVCs originating from RVOT
Number of subjects: 146
Study 24529550 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA using paclitaxel-coated balloon (PCB) and plain balloon (PB)
Number of subjects: 10
Study 24529550 — intervention group
Group type: COMPARATOR
Intervention: PTA using plain balloon (PB) alone
Number of subjects: 10
Study 21983758 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 60
Study 21983758 — intervention group
Group type: COMPARATOR
Intervention: Sodium thiopental
Number of subjects: 60
Study 19732677 — intervention group
Group type: COMPARATOR
Intervention: Transbond XT (3M Unitek) with 37% phosphoric acid etching (Control)
Number of subjects: 175
Study 19732677 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbond Plus and Transbond XT (3M Unitek)
Number of subjects: 175
Study 19732677 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil Mega Bond FA and Kurasper F (Kuraray Medical)
Number of subjects: 175
Study 19732677 — intervention group
Group type: EXPERIMENTAL
Intervention: Primers A and B, and BeautyOrtho Bond (Shofu)
Number of subjects: 175
Study 19732677 — intervention group
Group type: EXPERIMENTAL
Intervention: AdheSE and Heliosit Orthodontic (Ivoclar Vivadent AG)
Number of subjects: 175
Study 17362568 — intervention group
Group type: EXPERIMENTAL
Intervention: Automation-assisted cytological screening
Number of subjects: 777144
Study 17362568 — intervention group
Group type: COMPARATOR
Intervention: Conventional Papanicoalou (Pap) screening
Number of subjects: 777144
Study 15010181 — intervention group
Group type: EXPERIMENTAL
Intervention: Active coping (AC) stress task (reaction time task)
Number of subjects: 40
Study 15010181 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive coping (PC) stress task (cold-pressor test)
Number of subjects: 40
Study 15010181 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control condition
Number of subjects: 40
Study 15010181 — intervention group
Group type: EXPERIMENTAL
Intervention: Active coping (AC) stress task
Number of subjects: 40
Study 11181149 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-2 immunotherapy (4.5x106 IU twice daily for 5 days every 6 weeks)
Number of subjects: 13
Study 9754145 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg/day)
Number of subjects: 17
Study 9754145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7841259 — intervention group
Group type: EXPERIMENTAL
Intervention: Letters from general practitioners
Number of subjects: 1123
Study 7841259 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone reminders
Number of subjects: 1123
Study 7841259 — intervention group
Group type: COMPARATOR
Intervention: Postal reminders
Number of subjects: 1123
Study 3346069 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 27
Study 3346069 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 27
Study 29202606 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored narrative educational videos
Number of subjects: 40
Study 27016659 — intervention group
Group type: EXPERIMENTAL
Intervention: Active sequential bilateral rTMS
Number of subjects: 49
Study 27016659 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 49
Study 26308227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 3: Baseline intervention plus a pharmacist call to members' providers
Number of subjects: 6591
Study 26308227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 2: Baseline intervention plus a live outbound intervention call to members by a pharmacist
Number of subjects: 6591
Study 26308227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort 1: Baseline intervention consisting of member educational mailing and provider educational mail or fax notification
Number of subjects: 6591
Study 23613825 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng 1 g day(-1)
Number of subjects: 90
Study 23613825 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng 2 g day(-1)
Number of subjects: 90
Study 23613825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 23613825 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng
Number of subjects: 90
Study 23613825 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng 1 g
Number of subjects: 90
Study 20945821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Number of subjects: 156
Study 20945821 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline infusions)
Number of subjects: 156
Study 17426347 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic Auditory Stimulation (RAS)
Number of subjects: 78
Study 17426347 — intervention group
Group type: COMPARATOR
Intervention: NDT/Bobath training
Number of subjects: 78
Study 15195497 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tryptorelin depot (Decapeptyl 3.75)
Number of subjects: 132
Study 15195497 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tryptorelin acetate daily (Decapeptyl 0.1 mg)
Number of subjects: 132
Study 15195497 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg tryptorelin acetate daily from day 21 of the cycle
Number of subjects: 132
Study 11468228 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12 treatment
Number of subjects: 140
Study 11468228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 9881806 — intervention group
Group type: EXPERIMENTAL
Intervention: Conductive Education (CE)‐based programmes
Number of subjects: 34
Study 9881806 — intervention group
Group type: COMPARATOR
Intervention: Traditional neurodevelopmental programmes
Number of subjects: 34
Study 8297196 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose treatment with 1200 mg of norfloxacin
Number of subjects: 113
Study 8297196 — intervention group
Group type: COMPARATOR
Intervention: Multiple-day treatment with 400 mg of norfloxacin twice daily for 7 days
Number of subjects: 113
Study 8297196 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous cure in women with high initial colony count
Number of subjects: 113
Study 8297196 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous cure in women with low initial colony count
Number of subjects: 113
Study 3177373 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous vancomycin therapy (1-g loading dose followed by 30 mg/L dialysate effluent)
Number of subjects: 90
Study 3177373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent vancomycin therapy (2 doses of 30 mg vancomycin/kg body weight, initial dose at diagnosis and second dose 1 week later)
Number of subjects: 90
Study 4392503 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-receptor blocking drugs (phentolamine and phenoxybenzamine)
Number of subjects: 20
Study 4392503 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate
Number of subjects: 20
Study 4392503 — intervention group
Group type: COMPARATOR
Intervention: Histamine dihydrochloride (intravenous infusion)
Number of subjects: 20
Study 29802530 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 831
Study 29802530 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg/day
Number of subjects: 831
Study 29802530 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 831
Study 27770799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bicarbonate to achieve serum bicarbonate levels of 24-28 mmol/L
Number of subjects: 145
Study 27770799 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 145
Study 25773554 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance rituximab (MR)
Number of subjects: 0
Study 25773554 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy (RIT)
Number of subjects: 0
Study 25773554 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 23020102 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on caregivers' feeding practices, including enhanced home-prepared recipes and food preparation and hygiene through group training, counselling, and home visits.
Number of subjects: 599
Study 23020102 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention on caregivers' feeding practices.
Number of subjects: 599
Study 20077145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics intervention
Number of subjects: 294
Study 18166490 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous arterial closure device (Prostar(R)) used in group A (19 patients)
Number of subjects: 40
Study 18166490 — intervention group
Group type: COMPARATOR
Intervention: Conventional open surgery in control group B (21 patients)
Number of subjects: 40
Study 16724579 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic formulation of zidovudine (AVIRO-Z 300 mg tablet)
Number of subjects: 68
Study 16724579 — intervention group
Group type: COMPARATOR
Intervention: Innovator product (Retrovir tablet)
Number of subjects: 68
Study 15491235 — intervention group
Group type: COMPARATOR
Intervention: risperidone
Number of subjects: 1150
Study 11238508 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg estradiol daily
Number of subjects: 26
Study 11238508 — intervention group
Group type: COMPARATOR
Intervention: 2 mg estradiol plus 10 mg dydrogesterone daily
Number of subjects: 26
Study 9542398 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunological rehabilitation through various therapeutic methods including drugs, plasmapheresis, hemosorption, electrophoresis, ultrasound.
Number of subjects: 0
Study 9542398 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta‐1‐trophoblastic glycoprotein in experiments.
Number of subjects: 0